Zymeworks Inc. (ZYME)

Over the past six months, Zymeworks' stock price has been influenced by earnings reports, regulatory approvals, strategic initiatives, leadership changes, analyst sentiment, insider activity, and overall stock performance. Key events include the FDA approval of Ziihera®, various earnings reports, analyst rating adjustments, insider selling, and stock volatility.

There is no explicit indication of significant demand seasonality for Zymeworks' products and services. Demand is primarily driven by medical need, regulatory approvals, and clinical trial outcomes, rather than seasonal consumer patterns.

Zymeworks, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative biotherapeutics for difficult-to-treat diseases like cancers, inflammation, and autoimmune disorders. Their primary product, Zanidatamab (Ziihera®), is a bispecific antibody targeting HER2 and has received accelerated FDA approval for second-line biliary tract cancer. The company has other product candidates in its pipeline and utilizes proprietary therapeutic platforms.

Zymeworks operates globally with headquarters in Middletown, DE, and has 4 sites in 3 countries worldwide.

Zymeworks generally has a positive brand reputation due to its diversified oncology pipeline, proprietary platforms, and global partnerships, further bolstered by the FDA approval of Ziihera®. However, the company has faced challenges, including the de-prioritization of ZW49 and BeiGene's withdrawal from a collaboration, as well as risks related to clinical trial failures and regulatory delays.

Zymeworks Inc. has 310 institutional owners and shareholders holding a total of 78,973,805 shares, with institutional ownership at 98.4% as of September 2025. Major institutional owners include EcoR1 Capital, LLC, Rubric Capital Management LP, and BlackRock, Inc.